Interview Interview Expert talks and scientific presentations by local and international clinicians and scientists. Published: Jul 15, 2020

Optimizing treatment of status epilepticus

Dr Husain discusses designing and performing various clinical trials for medications used to treat status epilepticus.

  1. Husain AM, Lee JW, Kolls BJ, et al. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol. 2018;83:1174-1185.
  2. Rosenthal ES, Claassen J, Wainwright MS, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017;82:342-352.

Dr Aatif M. Husain has reported the following commercial interests occurring within the past 12 months:
• Personal compensation for consulting: UCB Pharmaceuticals, Jazz Pharmaceuticals, Biogen Idec, Sage Therapeutics, Eisai Pharmaceuticals, Marinus Pharmaceuticals, and Neurelis Pharmaceuticals
• Research funding: UCB Pharmaceuticals, Biogen Idec, Sage Therapeutics, and Marinus Pharmaceuticals
• Royalties: Springer, Demos Medical Publishing, and Wolters Kluwer
• Editorship: Wolters Kluwer

Learn more

Epilepsy Critical Care epilepsy critical care status epilepticus EEG super-refractory status epilepticus